Aurora Cannabis, one of Canada’s largest licensed producers, is teaming up with McGill University on an international medical research project to study the effects of CBD.
CBD (cannabidiol), is a non-intoxicating compound found in cannabis. It has been gaining traction in the past few years due to its therapeutic effects.
This study will focus on CBD oil as a therapy for chronic pain and related anxiety and depression.
“Based on our extensive experience with more than 60,000 registered Canadian patients, we believe CBD to be one of the most impactful medical compounds to become legally available to people in need of non-addictive therapies to treat pain,” CEO of Aurora, Terry Booth, stated in a press release.
“We are very pleased to be working with Aurora on this project,” said Dr. Gabriella Gobbi, a leading researcher at the Faculty of Medicine of McGill University.
“The cannabis plant and its components are yet to be fully understood and more evidence-based studies are needed. While an increasing body of scientific and anecdotal evidence shows that CBD has substantial potential in medical applications without any addictive liability, this project will ultimately elucidate the mechanism and the clinical application of the CBD,” said Dr. Gobbi, who also noted that CBD oil is increasingly prescribed by physicians around the globe.
The project will receive funding from Quebec’s Ministère de l’Économie, de la Science et de l’Innovation (MESI), as well as a financial contribution from Aurora, which will also be proving the CBD oil.
Research institutions in Canada, Italy, and France will be participating in the project.
- Canada's largest cannabis company is testing CBD for pets
- Canopy Growth funds professorship and research at UBC
- High CBD cannabis oil is a promising treatment for pediatric patients
- OPS giving away cannabis to help treat opioid addiction (VIDEO)